GlaxoSmithKlineE Valuation
Is BIOC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIOC (EGP40.58) is trading above our estimate of fair value (EGP0.96)
Significantly Below Fair Value: BIOC is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOC?
Key metric: As BIOC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BIOC's PE Ratio? | |
|---|---|
| PE Ratio | 28.3x |
| Earnings | ج.م119.55m |
| Market Cap | ج.م3.39b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 5.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does BIOC's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.3x | ||
RMDA Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E | 22.4x | 30.2% | ج.م5.1b |
AXPH Alexandria For Pharmaceuticals & Chemical Industries | 6.7x | n/a | ج.م1.5b |
PHAR Egyptian International Pharmaceutical Industries | 6x | n/a | ج.م7.0b |
CPCI Kahira Pharmaceuticals & Chemical Industries | 6.1x | n/a | ج.م1.5b |
BIOC GlaxoSmithKlineE | 28.3x | n/a | ج.م3.4b |
Price-To-Earnings vs Peers: BIOC is expensive based on its Price-To-Earnings Ratio (28.3x) compared to the peer average (10.3x).
Price to Earnings Ratio vs Industry
How does BIOC's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BIOC is expensive based on its Price-To-Earnings Ratio (28.3x) compared to the African Pharmaceuticals industry average (10.2x).
Price to Earnings Ratio vs Fair Ratio
What is BIOC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 28.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIOC's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.